Kedalion Therapeutics Inc.

The rumor mill has started to turn again about the possibility of Novartis AG shedding some eye disease assets but reports of the death of ophthalmology research at the Swiss major would appear to b

Novartis AG will be hoping that its acquisition of Kedalion Therapeutics Inc. could be the catalyst that finally ignites Xiidra, its dry eye drug bought for $3.4bn upfront from Takeda Pharmaceutic

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmace

Rakuten Aspyrian Inc. has raised $150m in Series C venture capital to fund a Phase III clinical trial that it intends to start before the end of this year to test its laser-activated antibody conjuga